GlaxoSmithKline Announces US Filing For Mepolizumab
June 28 2017 - 10:47AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Wednesday announced a
regulatory submission for mepolizumab, used to treat the rare
disease Eosinophilic Granulomatosis with Polyangiitis, to be made
available in the U.S.
Shares at 1516GMT, down 34 pence, or 2%, at 1,664 pence valuing
the company at GBP81.86 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
June 28, 2017 11:32 ET (15:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024